Interpreting scores on multiple sclerosis-specific patient reported outcome measures (the PRIMUS and U-FIS)

Health and Quality of Life Outcomes

Volumn 8, Issue , 2010, Pages

  Twiss, James ^a   Doward, Lynda C ^a   McKenna, Stephen P ^a   Eckert, Benjamin ^b  

^a GALEN RESEARCH   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; INTERNAL CONSISTENCY; INTERRATER RELIABILITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PATIENT REPORTED INDICES FOR MULTIPLE SCLEROSIS; RATING SCALE; RECURRENT DISEASE; UNIDIMENSIONAL FATIGUE IMPACT SCALE;

ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOMETRICS; QUALITY OF LIFE; SELF-ASSESSMENT; SWITZERLAND;

EID: 77957690461     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-8-117     Document Type: Article

References (47)

1. Multiple Sclerosis International Federation (MSIF) [accessed 02.12.09]. About MS, Multiple Sclerosis International Federation (MSIF)., http://www.msif.org/en/about_ms/
2. Vollmer T. The natural history of relapses in multiple sclerosis. J Neurol Sci 2007, 256(Suppl 1):5-13.
3. Putzki N, Fischer J, Gottwald K, Reifschneider G, Ries S, Siever A, Hoffmann F, Kafferlein W, Kausch U, Liedtke M, Kirchmeier J, Gmund S, Richter A, Schicklmaier P, Niemczyk G, Wernsdorfer C, Hartung HP, . for the "Mensch im Mittelpunkt" Study Group Quality of Life in 1000 patients with early relapsing-remitting multiple sclerosis. Eur J Neurol 2009, 16:713-20. 10.1111/j.1468-1331.2009.02572.x, 19475754, for the "Mensch im Mittelpunkt" Study Group.
4. Murray JT. Multiple Sclerosis, the History of a Disease 2005, New York: Demos Medical Publishing.
5. Patten SB, Williams JVA, Barbui C, Metz LM. Major depression in multiple sclerosis a population based perspective. Neurology 2003, 61:1524-27.
6. Montel SR, Bungener C. Coping and quality of life in one hundred and thirty five subjects with multiple sclerosis. Mult Scler 2006, 13:393-401.
7. Ziemssen T. Multiple Sclerosis beyond EDSS: depression and fatigue. J Neurol Sci 2009, 277(Suppl 1):37-41. 10.1016/S0022-510X(09)70011-5, 19036389.
8. Doward LC, McKenna SP, Meads DM, Twiss J, Eckert BJ. The Development of Patient Reported Outcome Indices for Multiple Sclerosis (PRIMUS). Mult Scler 2009, 15(9):1092-1102. 10.1177/1352458509106513, 19556315.
9. Lerdal A, Celius EG, Krupp L, Dahl AA. A prospective study of patterns of fatigue in multiple sclerosis. Eur J Neurol 2007, 14:1338-43. 10.1111/j.1468-1331.2007.01974.x, 17903208.
10. Meads D, Doward L, McKenna S, Fisk J, Twiss J, Eckert B. The development and validation of the Unidimensional Fatigue Impact Scale (U-FIS). Mult Scler 2009, 15:1228-1238. 10.1177/1352458509106714, 19556314.
11. Pickard SA, Neary MP, Cella D. Estimation of minimally important differences in EQ-5 D utility and VAS scores in cancer. Health Qual Life Outcomes 2007, 5:70. 10.1186/1477-7525-5-70, 2248572, 18154669.
12. Crosby RD, Kolotkin RL, Williams GR. An integrated method to determine meaningful changes in health-related Quality of Life. J Clin Epidemiol 2004, 57:1153-1160. 10.1016/j.jclinepi.2004.04.004, 15567631.
13. Hajiro T, Nishimaru K. Minimal clinically significant difference in health status: the thorny path of health status measures?. Eur Respir J 2002, 19:390-391. 10.1183/09031936.02.00283402, 11936512.
14. U.S. Department of Health and Human Services Food and Drug Administration Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009, U.S. FDA; Clinical/Medical, Accessed 9th December 2009, U.S. Department of Health and Human Services Food and Drug Administration Guidance for Industry., http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf
15. Puhan MA, Frey M, Büchi S, Schünemann HJ. The minimal important differences of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease. Health Qual Life Outcomes 2008, 6:46. 10.1186/1477-7525-6-46, 2459149, 18597689.
16. Schunemann HJ, Griffith L, Jaeschke R, Goldstein R, Stubbing D, Guyatt GH. Evaluation of the minimal important difference for the feeling thermometer and the St. George's Respiratory Questionnaire in patients with chronic airflow obstruction. J Clin Epidemiol 2003, 56(12):1170-1176. 10.1016/S0895-4356(03)00115-X, 14680667.
17. Santanello NC, Zhang J, Seidenberg B, Reiss TF, Barber BL. What are minimal important changes for asthma measures in a clinical trial?. Eur Respir J 1999, 14:23-27. 10.1034/j.1399-3003.1999.14a06.x, 10489824.
18. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002, 19:398-404. 10.1183/09031936.02.00063702, 11936514.
19. Turner D, Schünemann HJ, Griffith LE, Beaton DE, Griffith AM, Critch JN, Guyatt GH. Using the entire cohort in the receiver operating characteristic analysis maximises the precision of the minimal important difference. J Clin Epidemiol 2009, 62:374-379. 10.1016/j.jclinepi.2008.07.009, 19013766.
20. Stargardt T, Gonder-Frederick L, Krobot KJ, Alexander CM. Fear of Hypoglycaemia: defining a minimum clinically important difference in patients with type 2 diabetes. Health Qual Life Outcomes 2009, 7:91. 10.1186/1477-7525-7-91, 2770562, 19849828.
21. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Methods to explain the clinical significance of health status measures. Mayo Clinic proceedings 2002, 77(4):371-383. 10.4065/77.4.371, 11936935.
22. Norman GR, Stratford P, Regehr G. Methodological problems in the retrospective computation of responsiveness to change: the lesson of Cronbach. J Clin Epidemiol 1997, 50:869-879. 10.1016/S0895-4356(97)00097-8, 9291871.
23. Cohen J. Statistical Power Analysis for the Behavioural Sciences 1977, New York: Academic Press.
24. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003, 41:582-92. Review, 10.1097/00005650-200305000-00004, 12719681.
25. Wyrwich KW. Minimal important difference thresholds and the standard error of measurement: is there a connection?. J Biopharm Stat 2004, 14:97-110. 10.1081/BIP-120028508, 15027502.
26. Beaton DE, Hogg-Johnson S, Bombadier C. Evaluating changes in health status: reliability and responsiveness of five generic health status measures in workers with musculoskeletal disorders. J Clin Epidemiol 1997, 50:79-93. 10.1016/S0895-4356(96)00296-X, 9048693.
27. Turner D, Schünemann HJ, Griffith LE, Beaton DE, Griffith AM, Critch JN, Guyatt GH. The minimal detectable change cannot reliably replace the minimal important difference. J Clin Epidemiol 2010, 63:28-36. 10.1016/j.jclinepi.2009.01.024, 19800198.
28. McKenna SP, Doward LC, Twiss J, Hagell P, Oprandi NC, Fisk J, Grand'Maison F, Bhan V, Arbizu T, Brassat D, Kohlmann T, Meads DM, Eckert BJ. International Development of the Patient-Reported Outcome Indices for Multiple Sclerosis (PRIMUS). Value Health 2010,
29. Doward LC, Meads DM, Fisk J, Twiss J, Hagell P, Oprandi N, Goodman J, Grand'Maison F, Bhan V, Gonzalez B, Txomin A, Kohlmann T, Brassat D, Eckert BJ, McKenna SP. International development of the Unidimensional Fatigue Impact Scale (U-FIS). Value Health 2010, 13(4):463-468. 10.1111/j.1524-4733.2010.00706.x, 20230543.
30. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-52.
31. Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, Syndulko K, Weinshenker BG, Antel JP, Confavreux C, Ellison GW, Lublin F, Miller AE, Rao SM, Reingold S, Thompson A, Willoughby E. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999, 122(Pt 5):871-82. 10.1093/brain/122.5.871, 10355672.
32. Gronwall DM. Paced Auditory Serial-Addition Task: a measure of recovery from concussion. Percept Mot Skills 1977, 44:367-373.
33. EuroQoL Group EuroQoL - a new facility for the measurement of health-related quality of life. Health Policy 1990, 16:199-208. 10.1016/0168-8510(90)90421-9, 10109801, EuroQoL Group.
34. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5 D and SF-6D. Qual Life Res 2005, 14:1523-1532. 10.1007/s11136-004-7713-0, 16110932.
35. Nunnally JC. Psychometric Theory 1978, New York: McGraw-Hill.
36. Anastasi A, Urbina S. Psychological Testing 1997, New Jersey: Prentice Hall.
37. Fitzpatrick R, Norquist JM, Jenkinson C. Distribution-based criteria for change in health-related quality of life in Parkinson's disease. J Clin Epidemiol 2004, 57:40-44. 10.1016/j.jclinepi.2003.07.003, 15019009.
38. Wyrwich KW, Nienaber NA, Tierney WM, et al. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care 1999, 37:469-478. 10.1097/00005650-199905000-00006, 10335749.
39. Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999, 52:861-873. 10.1016/S0895-4356(99)00071-2, 10529027.
40. Wyrwich KW, Tierney WM, Wolinsky FD. Using the standard error of measurement to identify important changes on the Asthma Quality of Life Questionnaire. Qual Life Res 2002, 11:1-7. 10.1023/A:1014485627744, 12003051.
41. Alvarez-Lafuente R, Garcia-Montojo M, De Las Heras V, Dominguez-Mozo MI, Bartolome M, Garcia-Martinez A, Arroyo R. A two-year follow-up study: multiple sclerosis functional composite versus expanded disability status scale. Mult Scler 2009, 15(Suppl 9):55-56.
42. Kragt JJ, Thompson AJ, Montalban X, Tintore M, Rio J, Polman CH, Uitdehaag BMJ. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS. Neurology 2008, 70:1084-1091. 10.1212/01.wnl.0000288179.86056.e1, 18184917.
43. Costelloe L, Hutchinson M. Is a 20% change in MSFC components clinically meaningful?. Mult Scler 2007, 13:1076. 10.1177/1352458507077618, 17895297.
44. Casanova B, Pascual A, Bernat A, Escutia M, Bosca I, Coret F. Learning effect on multiple sclerosis functional composite in daily clinical practice [abstract]. Mult Scler 2004, 10(Suppl 2):118.
45. Cella D, Hahn EA, Dineen K. Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res 2002, 11:207-221. 10.1023/A:1015276414526, 12074259.
46. Kwok T, Pope JE. Minimally important difference for patient-reported outcomes in psoriatic arthritis: Health Assessment Questionnaire and pain, fatigue, and global visual analog scales. J Rheumatol 2010, 37(5):1024-8. 10.3899/jrheum.090832, 20231193.
47. Colangelo KJ, Pope JE, Peschken C. The minimally important difference for patient reported outcomes in systemic lupus erythematosus including the HAQ-DI, pain, fatigue, and SF-36. J Rheumatol 2009, 36(10):2231-7. 10.3899/jrheum.090193, 19723907.